Switching from fingolimod to alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis: Α case series.
Multiple Sclerosis and Related Disorders（2020）
Abstract
•Alemtuzumab appears to be effective in highly active MS cases who fail fingolimod.•Alemtuzumab may be beneficial for the treatment of disease flare-up post fingolimod.•One patient developed persistent lymphocytosis after alemtuzumab administration.
MoreTranslated text
Key words
Highly-active multiple sclerosis,Alemtuzumab,Fingolimod
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined